SynthesisFrontiers in immunology2026
Prevalence of female sexual dysfunction among women with systemic lupus erythematosus: a systematic review and meta-analysis.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prevalence of female sexual dysfunction (FSD) among women with systemic lupus erythematosus (SLE) is inconsistent, and whether SLE is a risk factor for FSD among women remains controversial. Therefore, this study aimed to conduct a systematic review and meta-analysis to estimate the prevalence of FSD among women with SLE and further explore the association between SLE and FSD. Methods: Literature on the prevalence of FSD among women with SLE was retrieved from PubMed, Web of Science, Cochrane Library, and Embase databases from inception to July 1, 2025. The pooled prevalence was calculated using a random-effects model for the meta-analysis. The Cochran Results: This meta-analysis included 13 studies involving 1,511 women with SLE and 2,246 healthy controls. The pooled prevalence of FSD among women with SLE was 58.8% (95% confidence interval [CI], 0.461-0.716). Compared with the healthy control group, women with SLE had a significantly increased risk of FSD (odds ratio, 2.64; 95% CI, 1.27-5.47). Conclusion: This systematic review and meta-analysis demonstrated a high prevalence of FSD among women with SLE and a significant association between SLE and an increased risk of FSD. Systematic review registration: https://inplasy.com/inplasy-2025-7-0092/,identifier 202570092.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.